Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
Sponsor
National Cancer Institute (NCI)
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02876640
This phase 1b trial studies the biologic effect of 9cUAB30 on early stage breast cancer. 9cUAB30 is a retinoid X receptor (RXR)-selective retinoid that acts in a tissue selective manner with the goal of minimizing side effects, a necessary feature of agents under development for cancer prevention.
Intervention
Biospecimen Collection, Retinoid 9cUAB30, Therapeutic Conventional Surgery
Condition
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Early Stage Breast Carcinoma, Invasive Breast Carcinoma
Investigators
Helen Krontiras